Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
Pharmaceutical Profiles of the UK has completed a groundbreaking study that bundles together a number of tests used to decide whether a drug development candidate is worth pursuing into a single clinical trial.
Clinical trials that support the effectiveness of drugs filed for approval in the US are more likely to be published than those that are less supportive, according to researchers at the University of California at San Francisco.
eClinical specialist Phase Forward has added to its portfolio by purchasing interactive-response technology company Clarix for $40m in cash in a move aimed at toppling ClinPhone from its leading position in the sector.
Like many of its peers in the contract clinical research sector, data management specialist Phase Forward put in another bumper financial performance in the second quarter headed by a 30 per cent hike in revenues to $41m.
Newly-released data appears to add weight to the case for
microdosing as a means to more accurately predict pharmacological
dose absorption, metabolism, distribution and elimination (ADME)
and pharmacokinetic (PK) outcomes in drug...
As eClinical gathers momentum, Outsourcing-Pharma.com spoke to two
contract research organisations (CROs), Icon and Parexel, to get
their views on the present and future of these emerging